期刊文献+

高亲和力的人源化CD20单克隆抗体的研究进展

下载PDF
导出
摘要 抗肿瘤抗体药物已成为癌症治疗中重要的策略之一,目前有多个抗CD20分子的单克隆抗体用于B细胞非霍奇金淋巴瘤(non Hodgkin's lymphoma,NHL)的临床治疗。本文综述CD20单抗药物的免疫原性和亲和力及其进展,探讨其未来的发展前景。
出处 《生物学教学》 北大核心 2017年第6期8-9,共2页 Biology Teaching
基金 国家高技术研究发展计划“动物细胞大规模批次流加培养关键技术及产品研发”,No.SS2012AA020704
  • 相关文献

参考文献2

二级参考文献31

  • 1侯梅,李潞,邱萌,鄢希,朱江,勾红峰.ProMACE-CytaBOM方案与CHOP方案治疗非霍奇金淋巴瘤的随机对照研究[J].癌症,2005,24(4):461-464. 被引量:6
  • 2郑美芳.改良的ProMACE/CytaBOM方案治疗非霍奇金淋巴瘤的疗效观察[J].四川肿瘤防治,2005,18(3):177-178. 被引量:1
  • 3梁敏,尚勇,龚启英.ProMACE-CytaBOM方案治疗非霍奇金淋巴瘤的近期疗效观察[J].中国医师杂志,2006,8(1):136-137. 被引量:2
  • 4郑岑.ProMACE-CytaBOM方案治疗非霍奇金淋巴瘤的临床观察与护理[J].解放军护理杂志,2006,23(3):56-57. 被引量:3
  • 5Wang M,Rule SA,Martin P,et al.Interim results of an international,multicenter,phase 2study of bruton's tyrosine kinase(BTK)inhibitor,Ibrutinib(PCI-32765),in relapsed or refractory mantle cell lymphoma(MCL):durable efficacy and tolerability with longer follow up[J].ASH Annual Meeting Abstracts,2012,120:904.
  • 6Byrd JC,Furman RR,Coutre S,et al.The bruton's tyrosine kinase(BTK)inhibitor Ibrutinib(PCI-32765)promotes high response rate,durable remissions,and is tolerable in treatment naive(TN)and relapsed or refractory(RR)chronic lymphocytic leukemia(CLL)or small lymphocytic lymphoma(SLL)patients including patients with high-risk(HR)disease:new and updated results of 116 patients in a phase Ib/II study[J].ASH Annual Meeting Abstracts,2012,120:189.
  • 7Wilson WH,Gerecitano JF,Goy A,et al.The bruton's tyrosine kinase(BTK)inhibitor,Ibrutinib(PCI-32765),has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma(DLBCL):interim results of a multicenter,open-label,phase 2study[J].ASH Annual Meeting Abstracts,2012,120:686.
  • 8Friedberg JW,Vose JM,Kelly JL,et al.The combination of bendamustine,bortezomib,and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma[J].Blood,2011,117:2807-2812.
  • 9Goy A,Bernstein SH,Kahl BS,et al.Bortezomib in patients with relapsed or refractory mantle cell lymphoma:updated time-to-event analyses of themulticenter phase 2 PINNACLE study[J].Ann Oncol,2009,20:520-525.
  • 10Fisher RI,Bernstein SH,Kahl BS,et al.Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma[J].J Clin Oncol,2006,24:4867-4874.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部